The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs.

**WEDNESDAY, AUGUST 7, 2019**

President Cyndi Vipperman called the meeting to order at 8:37AM

**Roll Call**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyndi Vipperman</td>
<td>President</td>
</tr>
<tr>
<td>Shannon Beaman</td>
<td>Vice President</td>
</tr>
<tr>
<td>Roberto Linares</td>
<td></td>
</tr>
<tr>
<td>Michelle Murray</td>
<td></td>
</tr>
<tr>
<td>Wassim Ayoub</td>
<td></td>
</tr>
<tr>
<td>Dianne Armstrong</td>
<td></td>
</tr>
<tr>
<td>Tim Logan</td>
<td></td>
</tr>
<tr>
<td>Rachael DeBarmore</td>
<td></td>
</tr>
<tr>
<td>Public Member - Vacant</td>
<td></td>
</tr>
</tbody>
</table>

The following staff members will be present for all or part of this session:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Schnabel, Executive Director</td>
<td>Brianne Efremoff, Compliance Director</td>
</tr>
<tr>
<td>Karen MacLean, Administrative Director</td>
<td>Chrisy Hennigan, Licensing Manager</td>
</tr>
<tr>
<td>Fiona Karbowicz, Pharmacist Consultant</td>
<td>Rachel Melvin, Operations Policy Analyst</td>
</tr>
<tr>
<td>Joe Ball, Chief Investigator</td>
<td>Cheryl Fox, Inspector</td>
</tr>
<tr>
<td>Jane Gin, Inspector</td>
<td>Katie Baldwin, Inspector</td>
</tr>
<tr>
<td>Laura Elvers, Inspector</td>
<td>Brian Murch, Inspector</td>
</tr>
<tr>
<td>Annette Gearhart, Compliance Secretary</td>
<td>Kim Oster, Compliance Coordinator</td>
</tr>
<tr>
<td>Loretta Glenn, Management Secretary</td>
<td>Tom Cowan, Sr. AAG Board Counsel</td>
</tr>
</tbody>
</table>

Annual Board Photos - Kim Oster took individual and group photos of the Board Members and Joe Schnabel.

Board President Cyndi Vipperman read the Board Member installation speech and a bio for new Board Member Michelle Murray. Welcome Michelle!

**Agenda Review and Approval**

**MOTION**

Motion to approve the agenda was made and unanimously carried (Motion by DeBarmore, seconded by Armstrong).

Board Counsel Tom Cowan provided brief comments on Administrative law and his role for the Board for our new Board Member.
EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.175, ORS 192.660 (1) (2) (f) (L).

A. Items for Consideration and Discussion:
   1. Deliberation on Disciplinary Cases and Investigations
   2. Personal Appearances
   3. Deficiency Notifications
   4. Case Review

MOTION
Motion to enter Executive Session at 8:58AM was made and unanimously carried (Motion by Beaman, seconded by Logan).

MOTION
Motion to resume Open Session at 4:15PM was made and unanimously carried (Motion by DeBarmore, seconded by Beaman).

OPEN SESSION - PUBLIC MAY ATTEND

Adjourn

MOTION
Motion to adjourn at 4:16PM was made and unanimously carried (Motion by DeBarmore, seconded by Beaman).

THURSDAY, AUGUST 8, 2019

President Cyndi Vipperman called the meeting to order at 8:30AM

Roll Call
Cyndi Vipperman, President  Shannon Beaman, Vice President
Roberto Linares               Michelle Murray
Wassim Ayoub                 Dianne Armstrong
Tim Logan                    Rachael DeBarmore
Vacant Public Member

The following staff members will be present for all or part of this session:
Joe Schnabel, Executive Director  Brianne Efremoff, Compliance Director
Karen MacLean, Administrative Director  Chrissy Hennigan, Licensing Manager
Fiona Karbowicz, Pharmacist Consultant  Rachel Melvin, Operations Policy Analyst
Joe Ball, Chief Investigator      Cheryl Fox, Inspector
Jane Gin, Inspector               Katie Baldwin, Inspector
Cyndi Vipperman introduced new Board Member and read a bio for Michelle Murray.

Motions for Cases & Disciplinary Action

GENERAL ADMINISTRATION

PDMP Follow-up –

Joe Schnabel gave a brief update to follow-up on the PDMP data entry accuracy issues presented at the June Board Meeting. He led a brainstorming exercise called a fishbone (Ishikawa) diagram and asked for Board input to identify contributing factors to the inaccurate data being reported to PDMP. The goal was to determine the root causes, problem solve the causes and create best practices to help improve the integrity of the data.

- **Technology**
  - Over formatting data fields
  - Error reports from PDMP
  - Need easier F/U reporting from PDMP & pharmacy to correct data
  - Interface issues
  - Different data fields between Rx and PDMP
  - Manual vs. upload data entry
  - MD gives wrong DEA
  - Data transmission
  - Provider database overrides
  - Inability to fix records

- **Environment**
  - Education of staff/Lack of appreciation of issue
  - Workload priorities
  - PDMP may force entry of incorrect data to get Rx to process

- **People**
  - Providers transmitting incorrect DEA
  - Wrong provider last name
  - Provider database errors
  - Not using X-DEA properly
  - Lack of education on X-DEA, spaces, etc.
  - ND/Not scope of practice

---

**Outcomes**

- Consequences of Poor PDMP data
  - Regulatory Use Concerns
  - Public Health Policy
  - Adverse impact on patient care

---
Policy/Rule Discussions –

Fiona Karbowicz reviewed and discussed the revised rule language in Division 019 & 020. Rules are revised to appropriately reflect statutory authority for formulary and prescribing authority (ORS 689.645 and ORS 689.649) and well as implement 2019 SB 9 (emergency insulin). She stated the revisions provide clarity of processes and expectations for the various prescriptive authorities being addressed simultaneously.

The Board had a discussion regarding inspections and compliance and how staff plans to regulate these newly proposed rules. Joe Schnabel stated that the regulation and implementation and policy discussions could be discussed at upcoming meetings, including strategic planning. The Board clarified that though the Board may be looked to for the positive implementation of these processes, the offering of these services is voluntary and not mandated.

The Board had a brief discussion about the definition of the word “evidence” in regards to SB 9 elements and expectations for the pharmacist’s patient assessment and documentation. Additionally, the Board discussed issues regarding clinician diagnosis, including when inferred versus when reported and expectations for pharmacists exercising authorities under these processes. Oregon Pharmacists have many options of various legal authorities to invoke in order to respond to a patient need. At times, it may be best to act by assessing patients and prescribing pursuant to Division 020 and 019, whereas other times the use of collaborative practice agreements may suit the need better. It will be more important now than ever for all Oregon pharmacists to truly understand legal scope, in order to discern when to intentionally refer a patient to an appropriate clinician.

The Board briefly discussed and agreed on the use of the protocol template outlined by Fiona for items that were adopted in October 2018 to the Protocol and Formulary lists.

Fiona reported about the committee’s 7/12/2019 meeting, which included the recommendation to add male & female condoms, as well as ongoing work to three protocol items: smoking cessation, travel health, and non-occupational post exposure prophylaxis.

**MOTION**

Motion to send rules in OAR Chapter 855, Divisions 019 and 020 to rulemaking hearing was made and unanimously carried (Motion by Armstrong, seconded by Ayoub).

---

Legislative Update –

Joe Schnabel and Fiona Karbowicz gave a report on the bills that were passed and described the impacts to some of our rules to be reviewed in upcoming board meetings.

**SB 9** – Oregon pharmacist prescribing of emergency insulin and supplies

Joe Schnabel read a letter (see attached) from Peter Courtney, President of the Oregon Senate. Proposed rule language to Division 019 voted to send to September 2019 rulemaking hearing; OBOP will be in the position to approve an ACPE educational program; Staff plans outreach regarding the law & implementation, to include the legal directives and implementation realities/expectations.
SB 698 – Requirements take effect on 1/1/2021; The Board recommended a RAC for this topic which will include discussions regarding HB 2935 as well. Requires OBOP to consult with OHA in order to adopt rules for Rx labels and inserts for patients in both English and a language the patient can understand. A minimum of 14 languages to be included. Rules must also establish a list of statements for Rx labels that must be made available, which must also be re-evaluated every 10 years or as needed. Impact - 6.21% of Oregonians over age 5 (222,000 people) are LEP (limited English proficiency); LEP individuals are more likely to experience medication errors due to an inability to read or understand Rx labels. CA, NY, NC and TX require pharmacies to provide specific services to assist those with LEP.

HB 2935 – Prescription Reader; also see SB 698; a pharmacy shall notify a blind or visually impaired patient that a prescription reader device is available upon request, and that labels dispensed are compatible with the device. We will use outreach to inform stakeholders about this law.

HB 2011 – Requires cultural competency Continuing Education (CE) as a condition for license renewal for pharmacists and certified pharmacy technicians (RPH/CPT). Mandate becomes operative on 7/1/2021. This is a follow-up from 2013 HB 2611 (voluntary); OBOP plans to have a more global policy discussion for CE, to include a revised position statement (original Aug. 2014). It is expected that interns receive cultural competency education in their ACPE-accredited pharmacy programs. OHA has approved programs that would satisfy this requirement for pharmacists and other health professionals.

SB 71 – Animal Euthanasia - Background: In June 2018 the OVMEB (Oregon Veterinary Medical Examining Board) presented to OBOP updates to address the evolution of veterinary standards of practice for humane euthanasia. Oregon veterinarians are expected to comply with the American Veterinary Medical Association and the American Society of Shelter Veterinarians guidelines; however, Oregon regulations are not aligned. Standards address both the humane death of the animal, as well as the safety of the licensed individual performing the procedure, and describe the use of sedatives and analgesia (pain relief) to accompany the lethal dose of anesthesia (sodium pentobarbital, a sedative/hypnotic). The Board articulated their concern regarding the security of highly divertible controlled substance drugs in an outlet where a veterinarian is not required to be on site, nor even on staff. Regarding enforcement, we see OVMEB and DEA as partners.

Fiona reviewed the purposed rule draft language, these edits provide for sedatives and analgesics being added, and clarification of drug outlet registration and compliance expectations. We anticipate sending this to the November 2019 rulemaking and staff will bring back more information to the upcoming October Board meeting.

HB 2257 – PDMP
Many policy prerogatives related to PDMP and substance use disorders. Requires pharmacies to report clinical diagnoses made by medical professionals and reasons for prescriptions. Requires pharmacies to report Gabapentin prescriptions. Changes operative on 1/1/2020. Outreach to licensees is necessary.

HB 3273 – Statewide Drug Take Back Program - DEQ leads; OBOP “shall assist the Environmental Quality Commission in adopting rules” AND has inspection responsibilities and fining authority up to $10,000 per day that a covered manufacturer's drugs are sold in OR. OBOP to enter into an agreement with DEQ for OBOP's inspections and OBOP shall inform DEQ of non-compliance. Outreach to licensees is necessary.
SB 910 – Naloxone Signage - Law states “A retail or hospital outpatient pharmacy must provide written notice in a conspicuous manner that naloxone and the necessary medical supplies to administer naloxone are available at the pharmacy.” OHA can adopt rules for other drugs to be reported to PDMP. Naloxone to be reported to the PDMP, but will not be disclosed and will not show up on reports. Outreach to licensees is necessary

HB 3030 and SB 688 – Armed Services - Spouse Licensure (Temporary Authorization) - The law outlines criteria for validations needed and states that a temp authorization is not renewable. Annual report to legislative committee, to include numbers of temp authorizations issued, the amount of time to process and issue, and OBOP’s “efforts to implement and maintain a process to issue temp authorizations.”

SB 855 – Immigrants/Refugees - OBOP shall study the manner in which immigrants and refugees get licensed and shall develop & implement methods to reduce barriers to licensure, with the goal of removing barriers for licensure. OBOP shall report to the Legislative Assembly on our progress not later than11/30/2019.

SB 5529 – OBOP Budget Bill - Fees went into effect 7/1/19, we are actively recruiting for positions. Karen is hopeful to have more information for the Board in October.

Discussion Items:

Policy Discussion for Board Review - none

TCVP - none

Strategic Planning Update – Joe Schnabel facilitated a discussion where he presented an outline of the ongoing plan, including upcoming meeting actions. This meeting’s discussion focused on the Board’s mission, vision, and values. Joe Schnabel read the current mission statement, the statute and the current vision statements. The Board collectively shared ideas and opinions about possible revisions to the mission statement and will submit additional language revisions via Survey Monkey to discuss at the upcoming strategic planning meeting in November. Regarding the logistics, Karen MacLean reported that staff is working on securing a venue for the meeting as well as procuring a facilitator.

Annual Performance Progress overview – Karen MacLean explained the KPM’s and reviewed the results of the Board best practices performance report. Staff created Survey Monkey and compiled data that will be used to respond to the 2019 Annual report due October 1st.

OPEN FORUM –

Adjourn

Motion to adjourn at 3:59PM was made and unanimously carried (Motion by Beaman, seconded by DeBarmore).
FRIDAY, AUGUST 9, 2019

President Cyndi Vipperman called the meeting to order at 8:31AM

Roll Call
Cyndi Vipperman, President   Shannon Beaman, Vice President
Roberto Linares     Michelle Murray
Wassim Ayoub     Dianne Armstrong
Tim Logan      Public Member - Vacant
Rachael DeBarmore – Excused

The following staff members will be present for all or part of this session:
Joe Schnabel, Executive Director   Brianne Efremoff, Compliance Director
Karen MacLean, Administrative Director   Chrisy Hennigan, Licensing Manager
Fiona Karbowicz, Pharmacist Consultant  Rachel Melvin, Operations Policy Analyst
Joe Ball, Chief Investigator      Cheryl Fox, Inspector
Jane Gin, Inspector               Katie Baldwin, Inspector
Brian Murch, Inspector            Loretta Glenn, Management Secretary
Tom Cowan, Sr. AAG Board Counsel

General Administration - Discussion Items continued

APhA Contraceptive Training Request & Background

On 6/7/2019, the Board received an email seeking approval for APhA’s program entitled Increasing Access to Hormonal Contraceptive Products to satisfy requirements of ORS 689.689 and OAR 855-019-0415, which states that a pharmacist must complete an ACPE Board-approved training program related to prescribing injectable hormonal and self-administered hormonal contraceptives.

Each Board member received a detailed program outline of the modules, as well as each individual PDF resource discussed and linked throughout the program. Additionally, each Board member, key staff members, and volunteer members of the Board’s original contraceptive consultative committee were provided access to the APhA’s demo program and asked to evaluate it for the following elements:
- Provision of a thorough review of women’s reproductive health
- Provision of a robust therapeutics and pharmacologic review
- Comprehensive teaching of the “art” of patient assessment, evaluation and contraceptive product selection
- Preparation of the pharmacist to comply with all related Oregon laws and rules
- Utilization of interactivity and effective fundamentals of adult learning

Reviewers completed the modules and submitted their comments, which were compiled by staff. The Board discussed the program and gave their opinions and comparisons to the currently approved program. General consensus was that they would like more robust questions in the training, including important patient safety elements on when not to prescribe (how and when to refer).
The decision was made to send it back to APhA to respond to the requests and suggestion and to address the errors then schedule it for a second review at the next available Board meeting once ready for re-evaluation.

DCCT – Charitable Pharmacy request

Diabetes Community Care Team is requesting a waiver of the rule that prohibits a charitable pharmacy from distributing a drug that requires refrigeration. Fiona stated that this is a follow-up request from the June 2019 Board meeting where the Board requested specific details related to insulin donations. Staff provided a brief summary of similarly situated waiver requests and prior actions.

The Board discussed the concerns about cold chain custody, the need for these donations and how to make it safe for patients. Cyndi Vipperman invited Executive Director/PIC Julie Dewsnup of DCCT to speak with the Board to answer their questions. Julie stated that they are a new charitable pharmacy that started in July 2018 and that there is high demand for insulin. She stated that her organization is willing to do whatever the Board is requesting in order to make the Board feel confident in the cold chain custody.

The Board directed staff to follow up with DCCT to facilitate oversight of Board’s concerns:

- Utilization of a contract with donating practitioners to outline responsibilities
- Plans to inspect the donating practitioner’s refrigerator logs, when applicable
- Receipt of only new product and assurances that her agreements with nursing home facilities would include language that she could only accept donations that came directly from a pharmacy
- Retaining documentation of temperature at time of pickup and delivery.

MOTION
Motion to approve with conditions as discussed Diabetes Community Care Team (CP-0000015) request to waive OAR 855-044-0050(1)(j) for 2 years, with a 1 year follow up report to staff was made and unanimously carried (Motion by Beaman, seconded by Armstrong).

Rural Health Community Council appointment – The Board received one response to our request seeking a voluntary 2-year appointment to this committee.

MOTION
Motion to appoint Pharmacist Nancy Wiley to the Rural Health Coordinating Council for 2 years was made and unanimously carried (Motion by Linares, seconded by Ayoub).

Rules

Review Rulemaking Hearing Report & Comments – none
Consider Adoption of Rules – none
Consider Adoption of Temporary Rules – none
Rules Update – none
Consider rules and send to Rulemaking Hearing

**Division 045 & 006 – Drug Compounding & Definitions**
Fiona Karbowicz reviewed the drug compounding rule revisions and asked the Board for input and direction on all proposed language. A majority of the discussion centered on the policy directive for all compounding pharmacies to have accreditation at least every three years. The concerns included awareness of the financial burden, especially to independent pharmacies, the balance of costs, patient safety assurances and access to compounded drugs. Additionally, the Board discussed policy changes related to shared service allowances, in light of federal policy changes to manufacturing, repackaging, office use and veterinary medicine. Fiona stated that we do anticipate a completely revised self-inspection form for non-sterile and sterile compounding for 2020. The Board discussed and accepted the edits and agreed to send to an upcoming rulemaking hearing for public comment and input specifically on the accreditation section.

**MOTION**
Motion to send Compounding rule revisions in OAR 855 Division 045 to rulemaking hearing was made and unanimously carried (Motion by Beaman, seconded by Ayoub).

**ISSUES/ACTIVITIES**

**Board Meeting Dates**
- October 2-3, 2019 Portland
- November 6-7, 2019 Portland *(Strategic Planning – subject to change)*
- December 11-12, 2019 Portland
- February 5-7, 2020* Portland (*3-day meeting*)
- April 15-16, 2020 Portland
- June 17-18, 2020 Portland
- August 12-14, 2020* Portland (*3-day meeting*)
- October 14-15, 2020 Portland
- November 18-19, 2020 TBA *(Strategic Planning – subject to change)*
- December 16-17, 2020 Portland

**Rulemaking Hearing Dates**
(The following dates are reserved for potential rulemaking hearings, identified only for planning purposes, and approved by the Board. Actual Rulemaking Activities will be noticed as required by law and may deviate from this schedule as needed.)
- September 24, 2019
- November 26, 2019

**Committees/Meetings**

OSPA Annual Convention 10/5-6/2019 – Portland – Board staff to provide a Law Update presentation and booth; space available for an OBOP member to participate.

NABP Executive Officers Forum 10/1-2/2019 – Chicago – Joe Schnabel will attend

NABP District VI-VIII Mtg. 10/6-9/2019 – Boise - Shannon Beaman, Wassim Ayoub and Joe Schnabel will attend.
OSHP Fall Seminar 11/16/19 – Portland (booth) – Michelle Murray, Dianne Armstrong, Wassim Ayoub and Joe Schnabel will attend.

NABP Compliance Officer/Legal Counsel Forum -12/4-5/2019 – Brianne Efremoff will attend.

OSPA Lane Co. Mid-Winter CE Seminar – 2/15-16/2020 – Eugene

**Board Member/Staff Presentations**

Pharmacy Coalition – 6/18/19 and Professional Practice Roundtable – 6/12/19 – Joe Schnabel and Fiona Karbowicz attended and both were focused on legislative discussions.

Financial/Budget Report – Karen MacLean stated that she is still waiting for the final budget information and will provide it in October.

---

**Reports**

Board President/Members – N/A

Executive Director Joe Schnabel reported he attended the Opioid Task Force meeting and there are number of projects they are working on. He also stated that he has now completed his trial service.

Board Counsel Tom Cowan – N/A

Compliance Director Brianne Efremoff – 38% completed Inspections (February to February) 23 people in HPSP, #550 cases year to date.

Pharmacist Consultant Fiona Karbowicz gave an update on the revamped Public Health and Pharmacy Formulary Advisory Committee processes and items under development with the use of subject matter experts helping to guide. Next meeting scheduled for October 25, 2019.

Administrative Director Karen MacLean reported that she's been busy over the last few months working on biennium end/start up activities, the MyLicense Office (MLO) upgrade, orientation activities for Michelle Murray and Strategic Planning preparations, in addition to other day to day activities. Special kudos to Chrisy and Kim for their participation on the MLO project, they are on track and within budget for go live later this year.

Licensing Manager Chrisy Hennigan reported that the two vacant licensing representative positions have been filled. As of 8/6/19, 48% of the Wholesaler, Manufacturer, Drug Distribution Agent renewals have been received with 7 weeks remaining in the renewal cycle. The Agency’s current database data has been migrated to the new platform and system formatting is now taking place to prepare for testing. The plan is to have the 2019 Intern renewal be the first in the new system. Additionally, new online applications will be available for the pharmacists, pharmacy technicians and Certified Oregon Pharmacy Technicians. All agency Board Members and staff must complete the CJIS recertification training no later than September 4th to remain in compliance. Staff will be creating a new standard work to address the challenges and lessons we have learned over the last few audit cycles.
Operations Policy Analyst Rachel Melvin stated that she is continuing to cover 2 positions, Executive Support Specialist as well as her current role as Operations Policy Analyst. Busy completing end of fiscal year accounts payable, still working on getting BOX outsourcing agreement completed by vendor. We recently completed ESO IT Security Risk Assessment, and she's working with desktop support vendor, CTA to build new laptops/desktops and providing tech support in-house almost daily. Rachel attended Rulemaking and Rule Writing training in Salem, has been working on adding content to new website; having to go through one page and one form at a time and attending additional Leadership Team meetings in addition to working closely with Fiona and team on several projects.

Approve Consent Agenda*

NAPLEX Scores – Jan 1, 2019 – April 30, 2019
MPJE Scores – Jan 1, 2019 – April 30, 2019
License/Registration Ratification – May 22, 2019 – July 22, 2019
Pharmacy Technician Extensions
Board Minutes – June 5-6, 2019

**MOTION**

Motion to approve Consent Agenda was made and unanimously carried (Motion by Beaman, seconded by Armstrong).

---

XII. OPEN FORUM –

Natalie Gustafson from Lloyd Compounding Pharmacy shared useful insights to the Board regarding pharmacy compounding and accreditation for OBOP’s consideration.

Adjourn

**MOTION**

Motion to adjourn at 2:17PM was made and unanimously carried (Motion by Beaman, seconded by Armstrong).

Accepted by:

Joseph Schnabel, Pharm D., R.Ph.
Executive Director
Executive Session of the Board was held on Wednesday, August 7, 2019 to discuss Compliance cases, followed by motions on Thursday, August 8, 2019.

Board Members present for all or part of compliance session:
- Cyndi Vipperman, CPT, President
- Shannon Beaman, RPH, Vice President
- Dianne Armstrong, CPT
- Wassim Ayoub, RPH
- Rachael DeBarmore, RPH
- Roberto Linares, RPH
- Tim Logan, Public Member
- Michelle Murray, RPH
- VACANT, Public Member

Staff present for all or part of compliance session:
- Brienne Efremoff, RPH, Compliance Director
- Joe Ball, RPH, Chief Investigator
- Katie Baldwin, RPH, Board Inspector
- Laura Elvers, RPH, Board Inspector
- Cheryl Fox, RPH, Board Inspector
- Jane Gin, RPH, Board Inspector
- Brian Murch, RPH, Board Inspector
- Annette Gearhart, Compliance Secretary
- Kim Oster, Compliance Coordinator

Case 2018-0195 & 2018-0628  Motion to accept Stipulated Consent Order.
Motion by: Dianne Armstrong; Seconded by: Roberto Linares. Motion unanimously carried.

Case 2018-0278  Motion to grant request for reconsideration and withdraw Final Order by Default.
Motion by: Rachael DeBarmore; Seconded by: Roberto Linares. Motion carried with Dianne Armstrong opposed.

Case 2018-0281  Motion to accept Consent Order.
Motion by: Dianne Armstrong; Seconded by: Shannon Beaman. Motion unanimously carried.

Case 2015-0571  Motion to accept Consent Order.
Motion by: Dianne Armstrong; Seconded by: Roberto Linares. Motion unanimously carried.

Case 2016-0462  Motion to accept Consent Order.
Motion by: Rachael DeBarmore; Seconded by: Roberto Linares. Motion unanimously carried.

Case 2016-0464  Motion to accept Consent Order.
Motion by: Rachael DeBarmore; Seconded by: Tim Logan. Motion unanimously carried.

Case 2017-0018  Motion to grant request to work at three Board approved locations.
Motion by: Dianne Armstrong; Seconded by: Michelle Murray. Motion unanimously carried.
Case 2017-0559  Motion to deny request.
Motion by: Rachael DeBarmore; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2018-0038  Motion to deny request.
Motion by: Dianne Armstrong; Seconded by: Tim Logan. Motion unanimously carried.

Case 2018-0251  Motion to accept Consent Order.
Motion by: Rachael DeBarmore; Seconded by: Michelle Murray. Motion unanimously carried.

Case 2018-0727  Motion to close with Board direction.
Motion by: Tim Logan; Seconded by: Michelle Murray. Motion carried with Rachael DeBarmore recused.

Case 2019-0127  Motion to withdraw Notice of Proposed Disciplinary Action.
Motion by: Shannon Beaman; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2019-0138  Motion to deny request.
Motion by: Tim Logan; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2017-0550  Motion to ratify signed Consent Order.
Motion by: Tim Logan; Seconded by: Michelle Murray. Motion carried with Rachael DeBarmore recused.

Case 2019-0467  Motion to revoke intern license and impose $1,000 civil penalty per violation.
Motion by: Rachael DeBarmore; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2019-0234  Motion to deny technician license and impose $1,000 civil penalty per violation.
Motion by: Dianne Armstrong; Seconded by: Shannon Beaman. Motion unanimously carried.

Case 2019-0320  Motion to revoke technician license and impose $1,000 civil penalty per violation.
Motion by: Roberto Linares; Seconded by: Michelle Murray. Motion unanimously carried.

Case 2019-0047  Motion to revoke technician license and impose $1,000 civil penalty per violation.
Motion by: Dianne Armstrong; Seconded by: Tim Logan. Motion carried with Cyndi Vipperman opposed.

Case 2019-0361  Motion to revoke technician license and impose $1,000 civil penalty per violation.
Motion by: Rachael DeBarmore; Seconded by: Roberto Linares. Motion unanimously carried.

Case 2019-0351  Motion to deny pharmacist license and impose $1,000 civil penalty per violation.
Motion by: Dianne Armstrong; Seconded by: Roberto Linares. Motion unanimously carried.

Case 2019-0209  Motion to deny technician license and impose $1,000 civil penalty per violation.
Motion by: Dianne Armstrong; Seconded by: Michelle Murray. Motion unanimously carried.

Case 2019-0153  Motion to deny CPT license and impose $1,000 civil penalty per violation.
Motion by: Rachael DeBarmore; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2019-0435  Motion to deny technician license and impose $1,000 civil penalty per violation.
Motion by: Tim Logan; Seconded by: Dianne Armstrong. Motion unanimously carried.
Case 2019-0414  Motion to close with Board direction.
Motion by: Dianne Armstrong; Seconded by: Shannon Beaman. Motion unanimously carried.

Case 2019-0317  Motion to revoke technician license and impose $1,000 civil penalty per violation.
Motion by: Tim Logan; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2019-0436  Motion to deny technician license and impose $1,000 civil penalty per violation.
Motion by: Rachael DeBarmore; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2019-0231  Motion to revoke technician license and impose $1,000 civil penalty per violation.
Motion by: Michelle Murray; Seconded by: Roberto Linares. Motion carried with Rachael DeBarmore recused.

Case 2019-0357  Motion to deny technician license and impose $1,000 civil penalty per violation.
Motion by: Dianne Armstrong; Seconded by: Tim Logan. Motion unanimously carried.

Case 2019-0230  Motion to revoke pharmacist license and impose $1,000 civil penalty per violation.
Motion by: Dianne Armstrong; Seconded by: Tim Logan. Motion unanimously carried.

Case 2018-0689  Motion to suspend pharmacist license for seven days and impose $1,000 civil penalty per violation.
Motion by: Michelle Murray; Seconded by: Roberto Linares. Motion unanimously carried.

Case 2019-0175  Motion to impose $10,000 civil penalty per violation against outlet; and in
Case 2019-0546  Motion to impose a $1,000 civil penalty per violation against PIC.
Motion by: Tim Logan; Seconded by: Dianne Armstrong. Motion carried with Shannon Beaman recused and Wassim Ayoub opposed.

Case 2019-0180  Motion to close with Board direction.
Motion by: Rachael DeBarmore; Seconded by: Michelle Murray. Motion unanimously carried.

Case 2018-0788  Motion to impose $10,000 civil penalty per violation against outlet; and
Case 2019-0522  Motion to impose $1,000 civil penalty per violation against Pharmacist-in-Charge.
Motion by: Shannon Beaman; Seconded by: Rachael DeBarmore. Motion unanimously carried.

Case 2019-0055  Motion to impose $10,000 civil penalty per violation against outlet, and close case with Board direction.
Motion by: Michelle Murray; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2019-0228  Motion to close with Board direction.
Motion by: Rachael DeBarmore; Seconded by: Shannon Beaman. Motion unanimously carried.

Case 2019-0377  Motion to impose $10,000 civil penalty per violation against outlet; and in
Case 2019-0523  Motion to impose $1,000 civil penalty per violation against Pharmacist-in-Charge.
Motion by: Dianne Armstrong; Seconded by: Michelle Murray. Motion unanimously carried.

Case 2019-0223  Motion to close with Board direction.
Motion by: Tim Logan; Seconded by: Rachael DeBarmore. Motion unanimously carried.
Case 2018-0491  Motion to close with Board direction.  
Motion by: Rachael DeBarmore; Seconded by: Tim Logan. Motion unanimously carried.

Case 2019-0227  Motion to close with Board direction.  
Motion by: Dianne Armstrong; Seconded by: Rachael DeBarmore. Motion unanimously carried.

Case 2019-0328  Motion to close with Board direction.  
Motion by: Michelle Murray; Seconded by: Dianne Armstrong. Motion unanimously carried.

Case 2018-0408  Motion to close with Board direction.  
Motion by: Dianne Armstrong; Seconded by: Shannon Beaman. Motion carried with Cyndi Vipperman opposed.

Case 2018-0407  Motion to close with Board direction.  
Motion by: Michelle Murray; Seconded by: Dianne Armstrong. Motion carried with Cyndi Vipperman opposed.

Case 2018-0409  Motion to close with Board direction.  
Motion by: Shannon Beaman; Seconded by: Tim Logan. Motion carried with Cyndi Vipperman opposed.

Case 2018-0410  Motion to close with Board direction.  
Motion by: Dianne Armstrong; Seconded by: Shannon Beaman. Motion carried with Cyndi Vipperman opposed.

Cases: 2019-0498 and 2019-0499  Motion to revoke technician license and impose $1,000 civil penalty per violation.  
Motion by: Dianne Armstrong; Seconded by: Tim Logan. Motion unanimously carried.

Case 2019-0416  Motion to grant pharmacist license and close with Board direction.  
Motion by: Rachael DeBarmore; Seconded by: Dianne Armstrong. Motion unanimously carried.


Motion to impose $1,000 civil penalty per violation against technicians.  
Motion by: Dianne Armstrong; Seconded by: Rachael DeBarmore. Motion carried with Shannon Beaman recused in case 2019-0483.

Case 2019-0358 and 2019-0434  Motion to close with Board direction.  

Case 2019-0353, 2019-0354, and 2019-0417  Motion to revoke technician license and impose $1,000 civil penalty per violation.  

Case 2019-0420, 2019-0437, 2019-0459, and 2019-0413  Motion to deny technician license and impose $1,000 civil penalty per violation.  

Case 2019-0359 and 2019-0362  Motion to revoke pharmacist license and impose $1,000 civil penalty per violation.  
Motion by: Dianne Armstrong; Seconded by: Shannon Beaman. Motion unanimously carried.
Case 2019-0208 and combined cases 2017-0477 & 2019-0334.
Motion to ratify signed Stipulated Consent Orders.
Motion by: Rachael DeBarmore; Seconded by: Tim Logan. Motion unanimously carried.

Motion to accept the items on the consent agenda.
Motion by: Rachael DeBarmore; Seconded by: Dianne Armstrong. Motion unanimously carried.

Cases closed with Board direction:
and 2019-0423.
August 1, 2019

Executive Director Joseph Schnabel
Oregon Board of Pharmacy
800 NE Oregon St., Suite 150
Portland, OR 97232

Dear Director Schnabel and Oregon Board of Pharmacy,

On behalf of the Senate President’s Office and the Oregon State Legislature I appreciate the leadership and timely implementation of Senate Bill 9. This life saving health care concept could not be completed without the hard work and dedication from Oregon Board of Pharmacy and OSU/OHSU College of Pharmacy.

In recent months I have heard from doctors, professors and legislators across the country about how they can duplicate Senate Bill 9 in their own states. The rule making you will now do could become the best practice for emergency insulin access across the nation.

Most importantly, parents, caretakers and diabetics themselves have literally stopped me on the street to say how much this will improve their lives. Their stories are moving.

As pharmacists you are often the front line for many patients. You are the health care provider they see on a monthly, or even weekly, basis for their care. Being able to provide your patients with emergency insulin will save time, money, ER visits – and lives. Our work will save the State of Oregon, health insurance companies and our health system countless dollars by increasing accessibility to insulin in emergency situations.

Thank you to OSU/OHSU College of Pharmacy for working to coordinate the qualified experts and supportive content for this initiative in a timely matter as service to the State of Oregon. With this content, we can ensure that all diabetic patients in Oregon have access to their supplies, no matter what emergency situation may arise.

We appreciate the engagement and partnership with the Oregon Board of Pharmacy in ensuring the timely implementation of Senate Bill 9.

Thank you.

Respectfully,

Peter Courtney

Senate President Peter Courtney